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The role of autophagy in tumour
development and cancer therapy
Mathias T. Rosenfeldt and Kevin M. Ryan*
Autophagy is a catabolic membrane-trafﬁcking process that leads to
sequestration and degradation of intracellular material within lysosomes. It is
executed at basal levels in every cell and promotes cellular homeostasis by
regulating organelle and protein turnover. In response to various forms of
cellular stress, however, the levels and cargoes of autophagy can be
modulated. In nutrient-deprived states, for example, autophagy can be
activated to degrade cargoes for cell-autonomous energy production to
promote cell survival. In other contexts, in contrast, autophagy has been
shown to contribute to cell death. Given these dual effects in regulating cell
viability, it is no surprise that autophagy has implications in both the genesis
and treatment of malignant disease. In this review, we provide a
comprehensive appraisal of the way in which oncogenes and tumour
suppressor genes regulate autophagy. In addition, we address the current
evidence from human cancer and animal models that has aided our
understanding of the role of autophagy in tumour progression. Finally, the
potential for targeting autophagy therapeutically is discussed in light of the
functions of autophagy at different stages of tumour progression and in
normal tissues.
During the genesis of cancer, tumour cells
experience various forms of intracellular and
extracellular stress. This hostile situation results in
damage to cellular proteins, the production of
reactive oxygen species (ROS) and the replication
of cells with heritable DNA damage. Tumour cells
must therefore utilise homeostatic mechanisms in
order to maintain sufﬁcient energy and integrity
in order to survive. Macroautophagy (hereafter
referred to autophagy for simplicity) is one
process within the cell that can serve to support
these demands, through the lysosomal-mediated
degradation of cellular proteins and organelles.
This not only results in the removal of damaged
cellular constituents, but also, where required,
can provide the catabolic intermediates for
intracellular production of ATP when exogenous
energy supplies are limited (Refs 1, 2, 3).
As outlined above, it would seem that
autophagy, as a result of its prosurvival
function, could serve as a potent oncogenic
mechanism to promote tumour cell survival.
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in cell survival undoubtedly exists, evidence
also points to a tumour-suppressive role:
downregulation of several autophagy genes
occurs in human cancer, mouse models where
critical autophagy regulators have been
deleted support a role for autophagy in
tumour suppression, and autophagy has been
implicated in cell death and oncogene-induced
senescence (Refs 4, 5, 6, 7). A conundrum
currently exists, therefore, as to the role of
autophagy in cancer, with perhaps different
roles being played at different stages and
in different tumour types (Ref. 8).
Understanding this issue in great detail is
seemingly critical if we are to consider targeting
autophagy – either positively or negatively –
for therapeutic gain.
Mechanisms of autophagy
Autophagy when translated from the Greek
literally means ‘self-eating’, and comprises
a multistep process of sequestration and
subsequent degradation of intracellular material
within specialised compartments (Refs 9, 10).
Autophagy is orchestrated by a subset of genes
that were originally identiﬁed in yeast and are
called autophagy-related genes (ATG), many of
which have mammalian orthologues (Refs 10,
11). Autophagy can be divided into different
stages that ultimately result in lysosomal
breakdown of cytoplasmatic material: initiation;
autophagosome formation (nucleation,
elongation and completion); and maturation
and degradation. These are discussed in detail
below and depicted in Figure 1.
Initiation
Initiation in mammalian cells starts with the
activation of a serine/threonine kinase complex
that contains ULK1/2 (orthologues of the yeast
protein Atg1), ATG13 and FIP200 (RB1CC1)
This complex transfers signals from the
nutrient-sensing mTOR kinase (MTOR;
mammalian/mechanistic target of rapamycin)
to initiate autophagy (Refs 12, 13, 14, 15).
Inhibition of mTOR-induced phosphorylation of
ULK and ATG13 liberates the kinase activity of
ULK, which subsequently phosphorylates itself,
ATG13 and FIP200. The ULK complex then
accumulates at the initiating focus of vesicle
formation: the isolation membrane or
phagophore (Refs 13, 14, 15).
Autophagosome formation
Vesicle nucleation – the further development of
the isolation membrane/phagophore – critically
depends on the activity of the class III
phosphoinositide 3-kinase (PI3K-III) hVps34
(PIK3C3; the orthologue of yeast Vps34) and its
formation of a complex with Beclin 1 (yeast
Atg6) and p150/hVps35 (PIK3R4; yeast Vps15)
(Refs 16, 17).
Vesicle elongation and completion from the
isolation membrane/phagophore to a nascent
autophagosome and the completed, closed
autophagosome is mediated by two ubiquitin-
like conjugation systems: the ATG12 and ATG8
conjugation systems (Ref. 18). The ubiquitin-like
ATG12 is activated by ATG7 and then
temporarily binds to the E2-like enzyme ATG10
before being transferred to ATG5. ATG5 further
reacts with ATG16 to form a multimeric
complex of ATG12–ATG5–ATG16 (Refs 19, 20).
In mammalian cells, several orthologues of
yeast Atg8 have been identiﬁed: MAP1LC3
(LC3), GABARAPL2 (GATE16), GABARAP and
GABARAPL1 (ATG8L). They are subjected
to modiﬁcation steps similar to those of
their yeast counterpart. The processing of
the autophagosome marker LC3 has been
investigated most thoroughly, and its stepwise
conversion from a cytosolic to a membrane-
bound form is exploited for the experimental
measurement of autophagy (Ref. 21). LC3 is
synthesised as a precursor protein proLC3 and
is immediately processed to LC3-I by ATG4
through cleavage of the C-terminal amino acid.
LC3 maturation completes with the reversible
conjugation of LC3-I to phosphatidylethanolamine
(PE) at the C-terminus by ATG3 and ATG7 to
form LC3-II on the surface of autophagosomes
(Refs 19, 20).
Both the ATG12–ATG5–ATG16 complex and
LC3-II are essential for autophagy. The
ATG12–ATG5–ATG16 complex is required for
targeting of LC3 to the autophagosomal
membrane and accelerated conjugation of LC3
to PE. Atg8, the yeast counterpart of LC3,
controls the expansion of the phagophore and
the amount of Atg8 directly correlates to the
size of the autophagosomes (Refs 19, 22). The
different stages of autophagosome formation
are intertwined and difﬁcult to separate.
Therefore the assignment of the different ATGs
to corresponding stages and autophagic vesicles
is to some degree academic.
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Figure 1. Mechanisms of autophagy. Following an initiating event, ATGs orchestrate the formation of
autophagic vesicles from the phagophore/isolation membrane to the autophagosome and ﬁnally the
autolysosome. The ULK–ATG13–FIP200 and the Beclin-1–hVps34–p150 complexes mediate early
nucleation events, whereas the two ubiquitin-like conjugation systems (ATG5–ATG12 and LC3-II) direct
vesicle elongation and autophagosome formation. Cellular material is ﬁnally sequestered within the
autophagosome and thereby separated from the cytoplasm. Intracellular material is degraded in
autolysosomes, which result from a fusion of lysosomes with autophagosomes. Importantly, autophagy is
the complete process from initiation to degradation and not just the accumulation of autophagosomes.
Abbreviations: ATG, autophagy-related protein; Beclin 1, coiled-coil myosin-like Bcl-2-interacting protein;
FIP200, 200 kDa FAK family kinase-interacting protein; hVps34, human vacuolar protein sorting-associated
protein 34; LC3, (microtubule-associated protein) light chain 3; mTOR, mammalian/mechanistic target of
rapamycin; p150, regulatory subunit of hVps34; P, phosphorylation; ULK1/2, unc-51-like kinase 1/2.
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The maturation process encompasses the fusion
of autophagosomes with lysosomes to form the
end-stage vesicle of autophagy: the autolysosome.
Molecular mechanisms of autophagosome
maturation are only recently emerging and
involve the actions of lysosomal proteins
LAMP1 and LAMP2, the small GTPase
Rab7 (RAB7A), UVRAG (the protein product of
the ultraviolet-radiation-resistance-associated gene)
and others (Ref. 9). The tumour suppressor UVRAG
not only regulates the interaction of Beclin 1 and
hVps34 at the stage of vesicle nucleation but
also plays an important role in the maturation
step. UVRAG directs so-called tethering proteins
(i.e. proteins that connect the autophagosome to
its target) to the autophagosomal membrane
and thereby activates Rab7 to facilitate fusion
with lysosomes (Ref. 17).
The ﬁnal autolysosome is an acidic vesicle
wherein the intracellular material gets degraded
by lysosomal hydrolases, especially cathepsins.
Amino acids and other constituent parts
generated in this catabolic process are then
released from the autolysosome to fuel cellular
resources. In yeast, amino acid efﬂux is
mediated in part via Atg22 (Ref. 23). Although
mammalian lysosomal amino acid transporters
have been described, a clear orthologue of
Atg22 in these higher species is yet to be
deﬁned.
Autophagy and cancer – from human
mutations to mouse models
Malignant transformation of a normal cell into a
cancer cell results from accumulation of several
mutations that override cellular safeguard
mechanisms such as apoptosis or oncogene-
induced senescence (Ref. 24). Currently it is
unclear how autophagy is to be interpreted in
the context of cancer. As outlined above, the
unsolved paradox is that on the one hand its
cytoprotective traits could clearly promote
survival of both cancer and normal cells (Refs 1,
3), whereas on the other hand autophagy might
suppress tumour growth through its connection
to cell death, senescence and oxidative stress
(Refs 6, 7, 25, 26, 27, 28).
The genetic evidence that autophagy and
cancer are linked is overwhelming (Refs 11, 29, 30).
We detail here in a piecemeal fashion the data that
have accumulated from humans and mouse
models about the function of ATGs, their direct
binding partners and their roles in either
protecting against or promoting cancer.
Beclin 1
Beclin 1 (BECN1) is a critical autophagy-
regulating gene and provided the ﬁrst human
genetic link between autophagy and cancer. It is
monoallelically deleted in 50% of human
breast, ovarian and prostate cancers and
expressed only at low levels in brain tumours
(Refs 31, 32, 33). Subsequent studies of
genetically modiﬁed mice revealed that while
bi-allelic loss of Becn1 is embryonically lethal,
mice that retain one copy of the gene are viable,
but have a higher incidence of lymphomas,
lung and liver carcinomas, as well as mammary
hyperplasia and accelerated formation of
premalignant lesions induced by hepatitis B
virus, compared with wild-type animals
(Refs 34, 35). In addition, reintroduction of
BECN1 into human MCF7 breast carcinoma
cells, which express only trace amounts of
Beclin 1, restores their autophagic capacity and
inhibits their tumour-forming potential
(Ref. 32). Beclin 1 is therefore a haploinsufﬁcient
tumour suppressor (Refs 34, 35).
ATG5 and ATG7
ATG5 and ATG7 are two other critical autophagy
regulatorsthathave been deleted in experimental
animal models. Unlike complete deletion of
Becn1, deﬁciency in ATG5 or ATG7 is not
embryonically lethal and mice are born normal
without any apparent abnormalities; however,
both Atg5
2/2and Atg7
2/2 mice die within 24 h
after birth, presumably as a result of an
inability to compensate the neonatal starvation
period that occurs after being cut off from the
maternal circulation, when autophagy is
normally transiently upregulated (Refs 3, 36).
Mice hemizygous for either Atg5 or Atg7 are
born viable and develop normally. In contrast
to Becn1-hemizygous animals, however, they do
not develop tumours (Refs 3, 36). Intercrossing
tumour-prone mice to recently developed
conditional knockout mice for Atg5 and Atg7
(Refs 36, 37) will seemingly be required for the
spatial and temporal dissection of the
contributionofthesegenestocancerdevelopment.
ATG4
Yeast Atg4 has four mammalian orthologues, of
which ATG4C (autophagin-3) is most widely
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viable, survive the neonatal starvation period
and develop normally (Ref. 38). Upon nutrient
restriction they show organ-speciﬁc reduction of
autophagy in the diaphragm. Autophagic
activity at basal levels is normal. Spontaneous
tumours arise at the same frequency as in wild-
type controls; however, they do have a higher
susceptibility to develop ﬁbrosarcomas after
chemical carcinogenesis (Ref. 38). A functional
redundancy of the different ATG4 proteins in
mammals might explain the notion that ATG4C
deﬁciency does not alter basal autophagic
activity in vivo and the fact that ATG4C-deﬁcient
mice survive the neonatal starvation period
(Ref. 38).
UVRAG
UVRAG is a tumour suppressor gene that is
monoallelically deleted in a signiﬁcant
proportion of human colorectal carcinomas, and
UVRAG expression in human HCT116 colon
carcinoma cells reduces the tumourigenic
potential of these cells in xenograft studies
(Ref. 16). Furthermore, UVRAG is a target for
frameshift mutations in colorectal and gastric
carcinomaswithmicrosatelliteinstability(Ref.39).
A role for autophagy deﬁciency in intestinal
tumourigenesis is further supported by the fact
that frameshift mutations in other autophagy-
related genes – ATG2B, ATG5, ATG9B and ATG12
– have been found in up to 28% of human gastric
and colorectal cancers with microsatellite
instability (Ref. 40). However the signiﬁcance of
this ﬁnding is yet to be determined.
BIF1
BIF1 (SH3GLB1) is another protein that positively
regulates autophagy, through interaction with
UVRAG and Beclin 1 (Ref. 41). B1F1-knockout
mice are born viable and develop normally,
without any apparent abnormalities except for
an enlarged spleen. However they do have a
higher propensity to develop spontaneous
cancer (mainly lymphomas and to a lesser extent
solid tumours) at an average age of 12 months.
BIF1 is thus a positive regulator of autophagy
and a potential tumour suppressor (Ref. 41).
Summary
In summary, the available data from humans and
mousemodelswhereATGsortheirdirectpositive
modulators are lost or expressed at low levels
point towards a tumour-suppressive role of
autophagy. It is important to keep in mind,
however, that in all the above mouse models
autophagy inhibition involved deletion of the
gene in the target cells embryonically. As a
result, all the pathologies observed arose from
cells that had always had impaired autophagy.
These experiments thus do not clarify the role
of acute autophagy loss at a later
developmental stage, for instance in an
established tumour, a scenario that likely
occurs in vivo. In order to address this
important question, further analysis is therefore
required of conditional autophagy-deﬁcient
animals, by using inducible Cre recombinases
so that gene deletion can be achieved in the
adult animal in a tissue- and tumour-speciﬁc
manner.
Genetic regulation of autophagy in cancer
As indicated above, the control of autophagy is
multifactorial and incompletely understood, but
there is an emerging trend that tumour
suppressors induce autophagy whereas
oncogenes have the opposite effect (Refs 5, 42).
Many oncogenic and tumour-suppressive
effects impact ultimately on mTOR and
complexes of Beclin 1 and hVps34 (Beclin-1–
hVps34), which are central to autophagy
regulation in many contexts (Ref. 43). These
complexes therefore merit prior discussion in
order to fully understand the control of
autophagy by classic oncogenes and tumour
suppressors (Fig. 2).
mTOR is a gateway for the control
of autophagy
The serine/threonine kinase mTOR is a focal
point for the action of many oncogenic and
metabolic events as well as the control of
autophagy. Many regulators of mTOR
signalling, especially the PI3K–AKT–PTEN
pathway, are frequently deregulated in human
tumours (Ref. 44). mTOR is part of two
different protein complexes: mTORC1 and
mTORC2 (Ref. 45). These have different
components, most notably raptor (RAPTOR;
regulatory-associated protein of MTOR,
complex 1) for mTORC1 and rictor (RICTOR;
rapamycin-insensitive companion of MTOR,
complex 2) for mTORC2 (Refs 46, 47).
Activation of mTORC1 leads to protein
synthesis via the actions of S6K1
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polypeptide 1) and 4EBP1 (EIF4EBP1,
eukaryotic translation initiation factor 4E
binding protein 1). By contrast, mTORC2 is less
well understood. It activates AKT via
phosphorylation and enhances the expression
of HIF-1a (HIF1A; hypoxia-inducible factor
1a) (Refs 48, 49). While driving translation,
mTOR also inhibits autophagy and this
effect is mediated via mTORC1 and its
interaction with the ULK–ATG13–FIP200
complex. The net effect of mTOR activation is
cell growth, proliferation and cell survival
(Refs 45, 50).
Signalling networks of oncogenes and tumour suppressors that control autophagy
Expert Reviews in Molecular Medicine © Cambridge University Press 2009
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Figure 2. Signalling networks of oncogenes and tumour suppressors that control autophagy. (See next
page for legend.)
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target for the regulation of autophagy
mTOR activity is pivotal in determining whether
theneteffectfromsignalswithinthecellispro-or
anti-autophagic. Another important regulator,
downstream of mTOR, is the Beclin-1–hVps34
complex (Ref. 43). Beclin 1 was initially
identiﬁed as a Bcl-2 (BCL2)-binding protein and
was found to have tumour suppressor functions
(Ref. 32). It has emerged, however, that Beclin 1
function is multifaceted and not restricted to
the regulation of autophagy. It is part of a
multiprotein complex that regulates autophagy
through variation of its composition (Fig. 3).
Beclin 1 forms a heterodimer that is stabilised
via binding to antiapoptotic members of the
Bcl-2 family [Bcl-2, Bcl-XL (BCL2L1), Mcl-1
(MCL1)] through its Bcl-2-homology domain 3
(BH3) domain (Refs 51, 52). Monomerisation of
Beclin 1 is required for it to associate with and
activate the PI3K-III hVps34, which is critical
for the formation of autophagosomes.
Therefore, tumour-associated perturbations of
antiapoptotic Bcl-2 family members can cause
profound inhibition of autophagy by
preventing the formation of a Beclin-1–hVps34
complex (Ref. 53).
The Beclin-1–hVps34–p150 core complex
is complemented by different regulatory
proteins that bind to Beclin 1 through domains
other than BH3 and deﬁne its role in
autophagy. To date, three different forms of the
complex have been identiﬁed, all of which have
different functions. They contain either ATG14/
BARKOR (Beclin-1-associated autophagy-
related key regulator) or UVRAG alone, or
both UVRAG and Rubicon (RUN domain
and cysteine-rich domain containing). It has
been proposed that the ATG14/BARKOR-
containing complex targets hVps34 activity
towards the isolation membrane and thus
functions in autophagosome formation, and
that the UVRAG-containing complex promotes
autophagosome and endosome maturation
(Ref. 54). ATG14/BARKOR positively regulates
autophagy, promotes translocation of Beclin 1 to
autophagosomes and competes with UVRAG
for the same binding site on Beclin 1 (Ref. 55).
By contrast, the UVRAG- and Rubicon-
containing complex suppresses autophagosome
and endosome maturation (Refs 56, 57).
Knockdown of ATG14/BARKOR inhibits
autophagy whereas knockdown of Rubicon has
the opposite effect, providing further evidence
that Beclin 1 has multiple roles in autophagy
through the formation of complexes with
opposing actions (Fig. 3). Although
perturbation of Beclin 1 clearly has implications
for cancer, a role for ATG14/BARKOR in cancer
has not yet been deﬁned. AMBRA1 is another
protein that binds the Beclin-1–hVps34
complex, with a role in the regulation of
autophagy in neuronal development (Ref. 58).
However, as with ATG14/BARKOR, its role in
autophagy regulation has also not yet been
extended to cancer.
Figure2.Signallingnetworksofoncogenesandtumoursuppressorsthatcontrolautophagy.(Seeprevious
page for ﬁgure.) A multitude of pathways that are commonly deregulated in cancer control autophagy via its
master switches mTOR and the complex of Beclin 1 and hVps34 (Beclin-1–hVps34). Hypoxia and limited
nutrient supply are frequently encountered in tumours and lead to activation of autophagy via engagement
of the same networks. Autophagy-inducing regulators are depicted in green, inhibiting regulators in red, and
those that have a dual effect on autophagy in yellow. The asterisk indicates that the mechanism of Ras-
induced upregulation of autophagy in senescence remains to be fully elucidated. Abbreviations: AKT, RAC-
alpha serine/threonine-protein kinase; AMPK, AMP-activated protein kinase; ARHI, aplasia Ras homologue
member I (also known as DIRAS3 for DIRAS family, GTP-binding RAS-like 3); BAD, Bcl-2-associated
antagonist of cell death; Bcl-2, B-cell CLL/lymphoma 2 (apoptosis regulator); Bcl-XL, B-cell lymphoma-extra
large; Beclin 1, coiled-coil myosin-like Bcl-2-interacting protein; BIF1, endophilin B1; BNIP3(L), BCL2/
adenovirus E1B 19 kDa protein-interacting protein 3-(like); DAPK, death-associated protein kinase; DRAM1,
damage-regulated autophagy modulator protein 1; ERK, extracellular-signal-regulated kinase; HIF1,
hypoxia-inducible factor 1; MAP1B, microtubule-associated protein 1B; Mcl-1, induced myeloid leukaemia
cell differentiation protein; mTORC1, mTOR complex 1; p53, cellular tumour antigen p53; p73, tumour
protein p73; PDGFR, platelet-derived growth factors receptor; PDK1, 3-phosphoinositide-dependent protein
kinase 1; PI3K-I, phosphoinositide 3-kinase class I; PTEN, phosphatase and tensin homologue; Ras,
GTPase Ras; RTK, receptor tyrosine kinase; RHEB, Ras homologue enriched in brain; STK11, serine/
threonine-protein kinase 11 (also known as LKB1); TSC1, hamartin, tuberous sclerosis 1 protein; TSC2,
tuberin, tuberous sclerosis 2 protein; UVRAG, UV-radiation-resistance-associated gene.
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As outlined above, many oncogenes and tumour
suppressors exert opposing effects on autophagy,
often through direct or indirect regulation of
mTOR and Beclin-1–hVps34, but also through
currently unknown mechanisms. In the
following examples we outline the reported
effects of tumour-associated proteins on both
autophagy and apoptosis.
PI3K-I
PI3K-I (class I phosphoinositide 3-kinase) is a
lipid kinase activated via receptor tyrosine
kinases (RTKs) by multiple mechanisms
(Refs 44, 59). This leads to cell growth and cell
proliferation and the concomitant inhibition of
autophagy by activation of mTOR. Since RTKs
and their downstream effectors are frequently
mutated in cancer, activation in the PI3K-I
pathway is very common in sporadic tumours
(Ref. 59). Activated PI3K-I generates the
second messenger phosphatidylinositol 3,4,5-
trisphosphate [PtdIns(3,4,5)P3], which then
leads to activation/phosphorylation of AKT via
3-phosphoinositide-dependent protein kinase 1
(PDPK1/PDK1). AKT phosphorylates and
Regulation of autophagy by Beclin 1 complexes
Expert Reviews in Molecular Medicine © Cambridge University Press 2009
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Figure3.RegulationofautophagybyBeclin1complexes.Beclin1exertsitsfunctiononautophagyonlywithin
a multimeric protein complex. It has diverse protein-binding domains that allow the formation of different
complexes with opposing functions on autophagy. Certain stimuli, for example starvation, disrupt the
binding of Bcl-2 proteins from the BH3 domain of Beclin 1. Beclin 1 can then bind and activate the
phosphoinositide 3-kinase hVps34. Currently four regulators of the Beclin-1–hVps34 complex have been
identiﬁed that determine its pro- or anti-autophagic activity. Autophagy-inducing regulators/complexes are
depicted in green, inhibiting regulators/complexes in red, and those that have an undetermined role in
yellow. Abbreviations: AMBRA1, activating molecule in Beclin-1-regulated autophagy protein 1; ATG,
autophagy-related protein; BARKOR, Beclin-1-associated autophagy-related key regulator; Bcl-2, B-cell
CLL/lymphoma 2; Bcl-XL, B-cell lymphoma-extra large; Beclin 1, coiled-coil myosin-like Bcl-2-interacting
protein; BH3, Bcl-2 homology domain 3; ECD, evolutionarily conserved domain; Mcl-1, induced myeloid
leukaemia cell differentiation protein; Rubicon, RUN domain and cysteine-rich domain containing, Beclin-1-
interacting protein; UVRAG, ultraviolet-radiation-resistance-associated gene.
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which as a result permits RheB (RHEB) to
activate mTORC1 (Ref. 45). AKT can also
activate mTOR independently of TSC2, via
PRAS40 (AKT1S1; proline-rich AKT-substrate
40 kDa). In summary, the net effect of PI3K-I
activation is activation of mTOR with
subsequent inhibition of autophagy (Refs 45, 50).
PTEN
PTEN (phosphatase with tensin homologue) is
mutated in multiple cancer types and is the
major target for mutation in Cowden disease, a
cancer predisposition syndrome (Ref. 60). PTEN
negatively regulates PI3K-I and thereby
alleviates the inhibitory effects of mTOR on
autophagy. Consequently, inactivation of PTEN
suppresses autophagy. Loss of PTEN is the
most common mechanism of PI3K-I activation
and is the second most frequently mutated
tumour suppressor in human cancer (Ref. 61).
Ras–MEK–ERK
The Ras–MEK–ERK pathway is deregulated in
many cancers and has a central role in mTOR
activation independent of AKT. The oncogenic
small GTPase Ras has an ambiguous role in
autophagy. Oncogenic HRAS-V12 has been
reported to suppress protein degradation via
activation of PI3K-I in NIH3T3 cells (Ref. 62),
whereas in nontransformed IMR90 human
diploid ﬁbroblasts, HRAS-V12 induces
senescence with concomitant increased
autophagy (Ref. 7). The role of ERK (MAPK1,
mitogen-activated protein kinase 1) in
autophagy is also multifactorial. ERK has been
shown in different in vitro settings to induce
autophagy (Refs 63, 64, 65). Recent ﬁndings
indicate that this may occur through
upregulation of Beclin 1 and destabilisation of
mTOR via induction of TSC. Interestingly in
this context, basal activity of MEK (MAP2K1)/
ERK conferred basal levels of mTOR and Beclin
1 that were incapable of triggering autophagy
(Ref. 66). By contrast to these reports, however,
it has also been shown that ERK can inhibit
TSC2 and promotes tumourigenesis in vitro and
in vivo (Ref. 61).
STK11
STK11 (serine/threonine kinase 11; also known as
LKB1) is a tumour suppressor that is mutated in
patients with hereditary intestinal polyposis
(Peutz–Jeghers syndrome), which leads to a
cumulative lifetime risk of cancer at age 70 of
90% (Ref. 67). In addition, mutations in STK11
are found in a high percentage of sporadically
occurring lung malignancies. STK11 is a
positive regulator of autophagy through the
actions of AMPK (AMP-activated protein
kinase) and mTOR. Treatment of a mouse
model for Peutz–Jeghers syndrome
(heterozygous for Stk11) with the mTOR
inhibitor rapamycin signiﬁcantly reduced the
tumour burden (Refs 68, 69).
DAPK1
DAPK1 (death-associated protein kinase 1) has
tumour-suppressive functions and is
epigenetically silenced in a variety of human
tumours (Ref. 70). DAPK was believed to be a
positive regulator of autophagy through
interaction with LC3-interacting microtubule-
associated protein MAP1B and disruption of
the Beclin-1–Bcl-XL complex (Ref. 71). Recent
data, however, showed that DAPK is a positive
regulator of mTORC1 through interaction with
TSC2 (Ref. 72). How this ﬁnding relates to the
net effect of DAPK on autophagy has not been
examined.
ARHI
The tumour suppressor ARHI (aplasia Ras
homologue member I; also known as DIRAS3
for DIRAS family, GTP-binding RAS-like 3) is
downregulated in more than 60% of ovarian
cancer (Ref. 73). It induces autophagy by
upregulation of ATG4 and blocking PI3K-I and
therefore mTOR (Ref. 74). In addition, its
expression leads to tumour dormancy in
ovarian cancer xenograft models, which can be
reversed upon treatment with chloroquine, a
pharmacological inhibitor of lysosomal function
and, as a result, autophagy (Ref. 74).
p53
p53 (TP53) is a major tumour suppressor, being
mutated or lost in 50% of all human cancers
(Ref. 75). In response to various forms of
cellular stress, p53 becomes activated, leading
to multiple phenotypic effects including
induction of cell-cycle arrest and cell death
(Ref. 76). Since p53 has been shown to respond
to, and also to modulate, metabolic stress, it is
perhaps no surprise that p53 has also been
found to regulate autophagy (Refs 77, 78, 79).
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however, appears to be dependent on context.
When elevated by cellular stress, p53
accumulates in the nucleus and activates target
genes that mediate its tumour-suppressive
effects. One of these genes, DRAM1 (damage-
regulated-autophagy modulator), encodes a
phylogenetically conserved lysosomal protein
that promotes autophagy (Refs 77, 80, 81).
Interestingly, DRAM1 was also found to be
required for p53-induced programmed cell
death, although the mechanism underlying the
interplay between DRAM1, autophagy and
apoptosis is yet to be determined (Ref. 77). p73
(TP73), a closely related protein to p53, has also
been shown to modulate DRAM1 and
autophagy, although autophagy induced by p73
was found to be independent of DRAM1
(Ref. 82). Since this points to other target genes
of p53/p73 being involved in autophagy
regulation, it is interesting to note that sestrin 2
(SESN2) has also been linked to both p53 and
p73 (Refs 83, 84). In an independent study,
sestrins have been shown to modulate
mTOR through AMPK (Ref. 85). A link has
now also been reported between p53, sestrin 2
and autophagy (Ref. 86), although the role of
sestrin 2 in p73-driven autophagy is yet to
be explored.
In the absence of cellular stress, basal levels of
p53 have, in contrast, been shown to inhibit
autophagy. This effect, however, does not
involve gene activation and occurs through a
cytoplasmic mechanism at the endoplasmic
reticulum (Ref. 79). Pharmacological inhibition
or genetic ablation of p53, both in vitro and in
vivo, was shown to induce autophagy.
Although the induction and inhibition of
autophagy by p53 are mechanistically distinct
and therefore seemingly separable, it would be
interesting to study the balance of these two
effects when both are active – are they
opposing or mutually exclusive? In this regard,
it is interesting to note that certain tumour-
derived mutants of p53 can inhibit autophagy
through the cytoplasmic mechanism, but they
do not cause the activation of DRAM1 or
sestrin 2 that would be required for the
induction of autophagy (Ref. 87). In tumours
with mutant p53, therefore, it would be
conceivable that autophagy would be reduced
through both lack of induction as well as
enforced inhibition.
ARF
ARF [‘alternative reading frame’ of the CDKN2A
(INK4A) locus] is a bona ﬁde tumour suppressor
that is known to induce p53 levels following
oncogenic stress and as a result has been shown
to induce p53-dependent autophagy and
thereby to enhance cell death. ARF-induced
autophagy might therefore contribute to its
tumour-suppressive function (Ref. 88). ARF can
also induce autophagy in the absence of p53,
probably through interaction with Bcl-XL which
normally inhibits the Beclin-1–hVps34 complex
(Ref. 89). A smaller truncated form of ARF,
smARF (resulting from initiation from an
alternative internal methionine), has also
recently been found to modulate autophagy in
a p53-independent manner. In this context,
smARF is considered to induce autophagy at
mitochondria and causes induction of a cell
death dependent on autophagy genes (Ref. 90).
Others
In addition to the tumour suppressors and
oncogenes discussed above, which have been
shown to have an active role in autophagy
regulation, several other tumour-associated
factors could be postulated to modulate
autophagy given their connection to pathways
that have been previously implicated in
autophagy regulation. As an element of
speculation is involved, an exhaustive list of
such factors could be generated; we feel,
however, that the factors listed below are
worthy of discussion even if further studies are
required to clarify a connection to autophagy
regulation and the extent to which this may be
important for the role of the factor in tumour
development.
NF1
NF1 (neuroﬁbromin) is a tumour suppressor that
antagonises Ras, and loss-of-function mutations
of NF1 are associated with the familial
neuroﬁbromatosis type 1 tumour syndrome
(Recklinghausen disease), which is
characterised by development of benign
tumours of the nervous system, as well as a
more general predisposition to cancer (Ref. 61).
Complicating understanding of the role of NF1
is the fact that acute loss of NF1 in human
diploid ﬁbroblasts leads to a transient
upregulation of Ras, but ultimately suppresses
the Ras–PI3K-I pathway and leads to
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ysenescence. The senescent phenotype was also
found in lesions from patients with
neuroﬁbromatosis. Autophagy has not been
examined in this context but might well be
upregulated given its crucial role in senescence
(Ref. 91).
REDD1
REDD1 (regulated in development and DNA-
damage responses 1; DDIT4) is induced upon
hypoxia and inhibits mTORC1 through
activation of TSC1/TSC2. REDD1 expression is
decreased in 30% of breast and prostate
carcinomas and therefore mTOR inhibition by
REDD1 might prevent tumourigenesis. Indeed,
xenografts with loss of REDD1 promoted
tumour growth in nude mice (Refs 92, 93).
Given the impact of REDD1 on mTOR (Ref. 94),
it would be predicted that changes in REDD1
would affect autophagy, but this has not yet
been directly addressed.
Deptor
Deptor (DEPDC6) is a newly identiﬁed mTOR-
interacting protein with an unknown role in
autophagy. It is expressed at low levels in most
cancers but high levels in multiple myeloma
cells (Ref. 95). Deptor is negatively regulated by
mTORC1/2. Loss of Deptor leads to activation
of mTOR targets and AKT, whereas
overexpression inhibits mTORC1 but activates
PI3K-I–AKT signalling (Ref. 95).
Summary
In summary, the mTOR and Beclin-1–hVps34
complexes are targeted by a multitude of
different oncogenes and tumour suppressors,
which thereby regulate autophagy. New players
are constantly being identiﬁed and new links
are being made, making the regulation of
autophagy in cancer incredibly complex.
Mechanisms for how loss of autophagy
contributes to tumourigenesis
It is currently unclear how loss of autophagy
contributes to de novo tumour formation and
how to interpret autophagy in the context of
already established tumours. There is, however,
accumulating evidence as outlined above that
autophagy is a tumour-suppressive mechanism.
Several reports have now provided potential
explanations as to how autophagy may function
in tumour suppression, including roles in cell
death, senescence and the management of
metabolic stress.
Autophagy and cell death
The role and mechanisms of autophagy in
promoting cell survival in contexts such as
nutrient deprivation are unequivocal. It is also
without question that autophagy accompanies
cell death in certain scenarios, although the
exact contribution of autophagy is complex and
less well deﬁned. In systems where apoptosis
was inhibited, either genetically or
pharmacologically, cell death dependent on
ATGs was reported (Refs 96, 97); in other
words, inhibition of certain ATGs (ATG5,
Beclin 1, ATG7) suppressed cell death. In one
report, where cells were treated with the
caspase inhibitor zVAD-fmk to inhibit caspase-
dependent death, it was proposed that the cell
death was mechanistically driven via the
selective autophagic degradation of catalase,
which subsequently overloads the cell with
damaging ROS (Ref. 98). A more direct role of
ATGs in cell death has also been shown:
cleavage of ATG5 has been reported to occur
following cell death induction and this cleaved
form has a direct proapoptotic role (Ref. 99). This
could indicate, therefore, that in studies where
cell death has been compromised by ATG5
knockdown, incorrect conclusions may have
been drawn that the cell death observed was
dependent on autophagy. The generality of these
observations, however, is yet to be determined.
Clearance of dying cells during salivary gland
development in Drosophila melanogaster involves
autophagy and in this context it appears that the
full-blown cell death response is dependent on
caspases and ATGs (Ref. 100). Increasing
evidence also suggests a non-cell-autonomous
role of autophagy in cell death, which extends
the housekeeping functions of autophagy to a
multicellular level. In an in vitro mouse model of
embryonic development, inhibition of autophagy
prevented the upregulation of two important cell-
surface engulfment signals – phosphatidylserine
and lysophosphatidylcholine – in cells destined
to die (Ref. 101). At ﬁrst impression, inhibition
of autophagy in this system seems to result in
cell death, but it is really the energy-dependent
expression of engulfment signals that is
impeded, which causes the accumulation of
cellular corpses by default, that is at play.
Exogenous methylpyruvate is an alternative
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the low levels of ATP in autophagy-deﬁcient
cells, leading to expression of the aforementioned
engulfment signals. In an vivo context, it is
notable that embryonic Atg5-null mice display
reduced phagocytosis of dead cells in lung
and retinal tissue, pointing to the wider
implications of this phenomenon and to the
caution that should be employed when dying
cells seemingly arise following autophagy
inhibition (Ref. 101).
In all the above-mentioned examples, ATGs
facilitate cell death, but it is arguable that a
situation has not yet been observed where a
cell actually dies solely from autophagy.
Furthermore, as discussed above, the role of
autophagy in cell death is not restricted to
cell-autonomous effects. Therefore, the term
‘autophagic cell death’ (or programmed cell
death type II) has to be used with caution. It
has been suggested it be replaced with the term
‘cell death with autophagy’ as it is now widely
considered that autophagy can be a component
in cell death, perhaps as a permissive signal,
but not its sole perpetrator (Ref. 102).
Autophagy in cell cycle arrest, dormancy
and senescence
Sustained growth arrest, like programmed cell
death, is an important mechanism to counteract
tumour growth in vivo and has recently been
shown to be critically linked with autophagy
(Ref. 100). Senescence is a critical barrier against
malignant transformation and an important
effector programme of chemotherapy. It is
deﬁned as an irreversible cell cycle arrest of
viable and metabolically active cells following
various endogenous and exogenous stresses
(Ref. 103). In HRAS-V12-infected human
diploid ﬁbroblasts, autophagy is activated and
its inhibition resulted in delayed onset of the
senescent phenotype (Ref. 7). In a reciprocal
fashion, overexpression of the autophagic
protein ULK3 induced autophagy and
accelerated the onset of senescence (Ref. 7).
However, the exact role of ULK3 in autophagy
is currently unclear.
Tumour dormancy generally describes a phase
of apparent stasis in tumour growth and is
mechanistically subdivided into two models.
Single-cell dormancy is a phase of prolonged
cell cycle arrest that can be overcome upon cell-
autonomous genetic changes or alterations in
the microenvironment. According to the
micrometastasis model, tumour dormancy is a
balanced state of cell renewal and cell death
(Ref. 104). (Both dormancy and senescence are
not to be confused with quiescence, which is a
physiological normal resting state of a cell.)
ARHI expression induces autophagy and leads
to tumour dormancy in ovarian cancer
xenograft models, which can be reversed upon
treatment with chloroquine, a pharmacological
inhibitor of lysosomal function and therefore
autophagy (Ref. 74).
When taken together, these reports clearly
emphasise that growth arrest and autophagy
are intertwined, and tentatively posit that
autophagy and its role in senescence and
dormancy may be a facet of tumour
suppression in multiple cancers.
Autophagy and the management
of oxidative stress
Metabolic stress, as a result of either insufﬁcient
nutrient/oxygen supply or increased energetic
demands of rapidly dividing tumour cells,
induces autophagy as an alternative source of
energy and metabolites. Enhanced autophagy is
frequently found in hypoxic regions of tumours
and contributes to cell survival (Ref. 105).
Initially, it is therefore illogical how loss of
autophagy contributes to tumour formation
(Refs 32, 34, 35). The ﬁrst contribution to solve
this conundrum came from the observation that
metabolic stress promotes necrotic cell death in
vivo and in vitro within cells that are defective
in both autophagy and apoptosis. Necrotic cell
death was associated with a strong
inﬂammatory response, which ultimately
enhanced tumour growth (Ref. 105). This
therefore provides one explanation of how
autophagy may be tumour suppressive –
through its capacity to impede necrosis.
Whether this is a factor, however, downstream
of chemotherapeutic drugs that induce cell
death through necrosis is an interesting
question and worthy of further investigation
(Refs 106, 107). Meanwhile it is becoming
increasingly substantiated that autophagy
reduces oxidative stress, maintains protein and
organelle quality control and thereby limits
cellular damage (Refs 27, 28).
Metabolic stress leads to accumulation of ROS,
damaged proteins and damaged organelles such
as mitochondria (which are in turn additional
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when compensatory mechanisms fail.
Autophagy is a critical countermeasure
following metabolic insults and attenuates these
changes, thereby promoting cellular survival. In
different studies, autophagy-defective tumour
cells were indeed more susceptible to cell death
but, importantly, at the same time were also
more susceptible to genomic damage and
possessed greatly enhanced tumourigenic
potential when compared with autophagy-
competent cells in vivo (Refs 27, 28).
Sequestosome 1 (SQSTM1; p62) has been
identiﬁed as the critical molecular link between
defective autophagy, genomic instability and
tumourigenesis (Ref. 26). p62 is an adapter
protein that links polyubiquitinated proteins or
aggregates to ATG8/LC3 on the surface of
autophagosomes. Importantly, it is also a
decisive element in modulating different
molecular pathways, such as the nuclear factor
NF-kB pathway through recruitment of
different signalling molecules and the extrinsic
cell death pathway by promoting aggregation
of caspase 8 (Ref. 108). p62 is frequently
upregulated in human tumours and of utmost
importance in controlling oxidative stress and
tumour growth (Refs 26, 109). Tumour cells,
therefore, with impairment in both apoptosis
and autophagy preferably accumulate p62
under stress, which thereby promotes
tumourigenesis (Ref. 26). In a self-supporting
feedback loop, metabolic stress leads to
increased production of ROS that in turn were
responsible for accumulation of p62. p62 itself
was also causative for further oxidative
damage, accumulation of damaged
mitochondria, an enhanced induction of the
protein-folding machinery in the endoplasmatic
reticulum, and a DNA-damage response.
Elevated levels of p62 suppressed the activation
of target genes of NF-kB. In Ras-induced lung
tumours, p62 is essential for tumour formation,
but in contrast to the observation by Mathew
et al. (Ref. 26), inhibition of p62 led to impaired
NF-kB signalling (Ref. 110). These differences in
NF-kB activation are not readily explained and
may be due to the versatility of p62 in
activating different pathways (Ref. 109) or the
different cellular contexts. Nonetheless, p62
accumulation is clearly causative for
tumourigenesis and exempliﬁes how cancer
progression can be affected by the selective
autophagic degradation of a speciﬁc protein.
Figure 4 illustrates how the metabolic capacity
of autophagy might be the decisive factor for
proliferation control in tumourigenesis.
Autophagy and therapy – whether to
treat and, if so, how?
With regard to the complexity and dichotomy of
autophagy in cell death and tumour biology and
limited treatment data from in vivo studies, can
autophagy be modulated for the beneﬁt of
cancer therapy? As a result of the survival
effects of autophagy that were initially observed
in vitro, the suggestion would have been that
autophagy inhibition, in combination with
standard chemotherapy, would be beneﬁcial for
tumour therapy. When we consider, however,
the effects this may have on a necrosis-driven
protumour inﬂammatory response or the effects
on impeding cellular senescence, one would
perhaps aver that autophagy promotion would
be the way to go. Nonetheless, several recent
reports have shown that pharmacological
inhibition of autophagy with chloroquine might
be beneﬁcial for tumour therapy (Refs 74, 111).
The effects of chloroquine are, however, not
limited to autophagy inhibition, causing,
among other things, inhibition of lysosomal
function in general, and it is important to note
that in vivo genetic veriﬁcation that the effects
of chloroquine in these settings was through
modulation of autophagy is yet to be
established. In this regard, it is notable that a
separate study analysing the therapeutic
effectiveness of chloroquine revealed prodeath
effects of autophagy. In this context, inhibition
of caspases in an autophagy-deﬁcient
background, but not in autophagy-competent
cells, reduced the cell death seen following
chloroquine treatment. This would indicate,
therefore, that cell death downstream of
chloroquine in this setting is, in part, autophagy
dependent (Ref. 112).
Another study has also recently examined
the regulation of autophagy by a doxycycline
(Dox)-regulatable ARHI-encoding gene
(DIRAS3) in xenografts. Treatment of mice
carrying these xenografts with Dox causes
induction of ARHI and autophagy and this led
to reduced tumour growth compared with
untreated animals. Upon removal of Dox, ARHI
and autophagy were reduced and rapid tumour
outgrowth was observed. However, when ARHI
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Stress (metabolic, oncogenic, pharmaceutical)
Sufficient autophagy
Insufficient autophagy (genetically or pharmaceutically)
Tumour growth
ROS
p62 p62
p62
NF-κB
Stressed cell
Dying cell
Senescent cell
Autophagic cell
Necrosis
Genomic instability
Mutation
Macrophage
Inflammatory cytokines
Damaged mitochondrion
Damaged DNA
Cell death Senescence Survival
Figure 4.Autophagymanagescellular stresstocounteract tumourgrowth.Inautophagy-competentcells,
cellular stress leads either to cell death, growth arrest in the form of premature senescence, or survival. If the
autophagic capacity falls below a threshold that is necessary to maintain cell integrity, for example through
genetic alterations or pharmaceutical intervention, cells are unable to compensate metabolic stress. As a
result, necrotic cell death occurs and causes attraction of tumour-promoting macrophages. In surviving
cells, however, failure to clear p62 (sequestosome 1) and p62-associated aggregates results in further
accumulation of ROS (reactive oxygen species), damaged proteins and organelles, altered cell signalling and
DNA damage. Clinically, this phase might present as an initial tumour remission. However, the acquisition of
growth-promoting mutations in a subset of cells might potentially lead to more aggressive tumour cells.
Abbreviation: NF-kB, nuclear factor kB.
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chloroquine at the same time to inhibit
autophagy, xenograft growth was rapidly
diminished after withdrawal of Dox (and
chloroquine) (Ref. 74). Taken together, a
possible interpretation of these ﬁnding is
that ‘genetic’ and pharmacological ablation of
autophagy produce different results and
again point towards alternative or additional
therapeutic effects of chloroquine in different
contexts. More studies are therefore required
to understand the relevance of autophagy
following treatment with chloroquine in
different settings.
When considering targeting autophagy
therapeutically, the effects on normal as well as
tumour cells must always be considered. This is
no more relevant than with autophagy, which
has major homeostatic roles within our normal
tissues. For example, the selective ablation of
autophagy in the brains of mice has been
shown to lead to neurodegenerative disease
without any other accompanying mutation,
indicating that the systemic modulation of
autophagy may be naive (Refs 37, 113). As a
result, it seems clear that we perhaps need to
understand more about the selective control of
autophagy in different settings to enable the
bespoke targeting of autophagy to hit diseased
cells, but not normal tissue. An understanding
of the signalling pathways that talk to the
autophagy machinery in response to different
forms of cellular stress to bring about different
effects may therefore be the key. In this regard,
a recent report has identiﬁed that signalling
from PDGF (platelet-derived growth factor)
receptors is a permissive signal for hypoxia-
driven autophagy while seemingly having no
effects on autophagy driven by other stimuli.
Since autocrine PDGFR signalling and hypoxia
are both tumour-associated events this may
well be a paradigm for the identiﬁcation of
autophagic signalling pathways that could be
utilised for targeting tumour-selective
autophagy, and further studies of this, and
other pathways, undoubtedly merit further
investigation (Refs 114, 115; see also Fig. 2).
In summary, autophagy is important for
development and cellular homeostasis, and lies
at the intersection of life and death. More and
more evidence is accumulating, however, that
autophagy is a tumour-suppressive mechanism,
with bonds to the control of oxidative damage,
cell death and oncogene-induced senescence.
Looking at autophagy from a metabolism angle
provides explanation of how loss of a
cytoprotective mechanism facilitates tumour
development through mitigating genomic stress.
In line with these desired tumour-suppressive
functions, autophagy-enhancing therapy may
be as promising a therapeutic strategy as the
simple notion of inhibiting autophagy to
enhance cell death. It is undoubted, however,
that our current understanding of autophagy is
incomplete. As more genetic models of
autophagy inhibition are developed, which
allow the spatial and temporal control of
autophagy, this should enable the more effective
targeting of autophagy in a both a selective and
bespoke manner.
Acknowledgements and funding
We are grateful to members of the Tumour Cell
Death Laboratory for critical reading of the
manuscript. We also thank the peer reviewers
of our article, whose insightful comments
improved the clarity and comprehensive nature
of this review. Work in the Tumour Cell Death
Laboratory is supported by Cancer Research
UK and the Association for International
Cancer Research.
Note added in proof
The reader should be aware that in the context
of autophagy regulation as described in this
review, and despite what was previously
believed, a recent report has indicated that
autophagy can occur in the absence of both
ATG5 and ATG7 (Ref. 116). The generality of
this observation and what it means in terms
of the genetic analysis of autophagy as a
result of depletion/loss of ATG5, ATG7 or
both are certainly areas that merit further
investigation.
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yFurther reading, resources and contacts
A newly established forum on autophagy, hosted by the journal Autophagy, provides useful information on
reagents and antibodies used in autophagy research:
http://www.landesbioscience.com/journals/autophagy/forum/
The US National Cancer Institute website might prove useful for clinicians to gain a rapid overview of research
and clinical trials that are ongoing in the autophagy ﬁeld in the USA:
http://www.cancer.gov/
Likewise, the Cancer Research UK website provides similar information about research projects on autophagy
in the UK:
http://www.cancerresearchuk.org/
Further information about work in the authors’ laboratory and about The Beatson Institute for Cancer Research
in general can be found at:
http://www.beatson.gla.ac.uk/
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Figures
Figure 1. Mechanisms of autophagy.
Figure 2. Signalling networks of oncogenes and tumour suppressors that control autophagy.
Figure 3. Regulation of autophagy by Beclin 1 complexes.
Figure 4. Autophagy manages cellular stress to counteract tumour growth.
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